Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

5.41
+0.28005.46%
Pre-market: 5.500.0900+1.66%05:38 EDT
Volume:27.55M
Turnover:147.00M
Market Cap:2.23B
PE:-4.94
High:5.63
Open:5.02
Low:5.01
Close:5.13
52wk High:5.63
52wk Low:1.64
Shares:411.96M
Float Shares:339.00M
Volume Ratio:1.15
T/O Rate:8.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0941
EPS(LYR):-1.0941
ROE:-55.50%
ROA:-27.30%
PB:3.19
PE(LYR):-4.94

Loading ...

Stock Track | Iovance Biotherapeutics Soars 31.49% on Strong Q3 Results and Pipeline Progress

Stock Track
·
Nov 06, 2025

Iovance Biotherapeutics Showcases TIL Therapy Advances and Pipeline in New Corporate Presentation

Reuters
·
Nov 06, 2025

Stock Track | Iovance Biotherapeutics (IOVA) Surges 13.82% Pre-market on Strong Q3 Results and Revenue Growth

Stock Track
·
Nov 06, 2025

Stock Track | Iovance Biotherapeutics Soars 13.82% Pre-market on Strong Q3 Results and Revenue Growth

Stock Track
·
Nov 06, 2025

Iovance Biotherapeutics Q3 EPS $(0.25) Beats $(0.26) Estimate, Sales $67.455M Miss $72.402M Estimate

Benzinga
·
Nov 06, 2025

Iovance Biotherapeutics Reports 13% Revenue Growth and Improved Gross Margin in Q3 2025

Reuters
·
Nov 06, 2025

Iovance Biotherapeutics Inc: Full-Year 2025 Revenue Guidance Is Reaffirmed

THOMSON REUTERS
·
Nov 06, 2025

Iovance Biotherapeutics Q3 EPS USD -0.25 VS. Ibes Estimate USD -0.25

THOMSON REUTERS
·
Nov 06, 2025

Iovance Biotherapeutics Q3 Revenue USD 68 Million

THOMSON REUTERS
·
Nov 06, 2025

Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results

GlobeNewswire
·
Nov 06, 2025

Iovance Biotherapeutics Stock Rises Premarket on Positive Trial Data for Cancer Drug

Dow Jones
·
Nov 03, 2025

Iovance Biotherapeutics Reports 26% Response Rate for Lifileucel in Advanced NSCLC Trial

Reuters
·
Nov 03, 2025

Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel Til Cell Therapy in Advanced Non-Small Cell Lung Cancer (Nsclc)

THOMSON REUTERS
·
Nov 03, 2025

Iovance Biotherapeutics Inc: Iov-Lun-202 Trial to Advance in 2026 Toward Lifileucel Bla in Nonsquamous Nsclc

THOMSON REUTERS
·
Nov 03, 2025

Barclays Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)

TIPRANKS
·
Oct 31, 2025

Iovance Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 30, 2025

Iovance Biotherapeutics, Inc. : H.c. Wainwright Cuts Target Price to $9 From $20

THOMSON REUTERS
·
Oct 29, 2025

Iovance Biotherapeutics (IOVA): Examining Valuation Following Recent Signs of Share Price Stabilization

Simply Wall St.
·
Oct 28, 2025

Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025

GlobeNewswire
·
Oct 24, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Oct 18, 2025